UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its stake in AbCellera Biologics Inc. (NASDAQ:ABCL) by 0.2% during the third quarter, according to its most recent filing with the SEC. The fund owned 4,590,103 shares of the company’s stock after selling 8,523 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 1.55% of AbCellera Biologics worth $11,934,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ABCL. Renaissance Technologies LLC raised its position in AbCellera Biologics by 16.0% in the second quarter. Renaissance Technologies LLC now owns 1,728,603 shares of the company’s stock worth $5,117,000 after acquiring an additional 239,000 shares during the period. Intellectus Partners LLC increased its stake in shares of AbCellera Biologics by 0.7% during the 2nd quarter. Intellectus Partners LLC now owns 545,533 shares of the company’s stock worth $1,615,000 after purchasing an additional 3,750 shares during the last quarter. Citizens Financial Group Inc. RI bought a new stake in shares of AbCellera Biologics in the 2nd quarter worth approximately $923,000. Skandinaviska Enskilda Banken AB publ lifted its stake in AbCellera Biologics by 104.9% in the second quarter. Skandinaviska Enskilda Banken AB publ now owns 308,567 shares of the company’s stock valued at $913,000 after purchasing an additional 158,000 shares during the last quarter. Finally, GSA Capital Partners LLP grew its holdings in AbCellera Biologics by 991.3% during the third quarter. GSA Capital Partners LLP now owns 241,866 shares of the company’s stock valued at $629,000 after purchasing an additional 219,703 shares during the period. 61.42% of the stock is owned by hedge funds and other institutional investors.

AbCellera Biologics Price Performance

Shares of NASDAQ ABCL opened at $3.00 on Friday. The stock has a fifty day simple moving average of $2.75 and a two-hundred day simple moving average of $2.90. AbCellera Biologics Inc. has a 1-year low of $2.34 and a 1-year high of $6.05.

AbCellera Biologics (NASDAQ:ABCL) last issued its earnings results on Monday, November 4th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). AbCellera Biologics had a negative net margin of 533.32% and a negative return on equity of 15.73%. The business had revenue of $6.51 million for the quarter, compared to the consensus estimate of $8.95 million. During the same period in the previous year, the firm earned ($0.10) EPS. Equities research analysts expect that AbCellera Biologics Inc. will post -0.59 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ABCL has been the subject of several research reports. Stifel Nicolaus reissued a “buy” rating and set a $12.00 price objective (down from $14.00) on shares of AbCellera Biologics in a report on Tuesday, November 5th. Benchmark reissued a “hold” rating on shares of AbCellera Biologics in a report on Tuesday, November 5th.

AbCellera Biologics Company Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.